VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PRQR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PRQRProQR Therapeutics N.V.
$1.15$116M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksPRQRBalance Sheet

ProQR Therapeutics N.V. (PRQR) Balance Sheet

13Y historyFree accessUpdated daily

Leverage is modest with a debt-to-equity ratio of 0.17 and $13.2M of debt in 2026Q2, but the asset base is cash-dominated with $117.1M of $133.5M total assets, and $28.1M of deferred revenue represents collaboration obligations rather than free cash.

Income StatementBalance SheetCash FlowRatios

PRQR Balance Sheet

Annual statement

PRQR Balance Sheet

ProQR Therapeutics N.V. (PRQR) balance sheet — 13-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Total Current Assets121.58M117.59M159.31M133.65M164.85M217.75M97.91M128.71M123.88M60.71M65.41M97.77M113.9M4.26M
Cash & Short-Term Investments117.08M108.53M154.71M131.37M101.15M213.25M92.79M125.66M120.69M57.76M62.44M94.86M112.74M4.13M
Cash Only117.08M108.53M154.71M131.37M101.15M213.25M92.79M125.66M120.69M57.76M62.44M94.86M112.74M4.13M
Short-Term Investments00000000000000
Accounts Receivable1.86M5.97M2.1M1.4M61.09M935.91K978.84K1.34M2.45M563.17K1.65M1.5M426K130K
Days Sales Outstanding68.55142.740.5278.496.2K255.89347.21252.23180.88-134.44264.0258.32496.77-
Inventory00000000000547K327K0
Days Inventory Outstanding-----------413.49--
Other Current Assets000000000000-1.16M0
Total Non-Current Assets11.92M14.83M14.61M18.67M17.99M20.58M22.89M3.22M2.13M3.05M3.72M2.34M1.35M243K
Property, Plant & Equipment11.92M14.83M14.61M18.67M17.33M19.86M22.76M2.74M2.13M3.01M3.63M2.2M1.19M204K
Fixed Asset Turnover1.33x1.03x1.29x0.35x0.21x0.07x0.05x0.71x2.32x-0.51x0.63x4.28x0.26x-
Goodwill00000000000000
Intangible Assets00000000046.83K94.93K141K163K39K
Long-Term Investments0000662.76K715.3K130.92K481.55K000000
Other Non-Current Assets00000000000000
Total Assets133.5M132.43M173.92M152.31M182.84M238.33M120.8M131.93M126.01M63.77M69.13M100.11M115.25M4.5M
Asset Turnover0.14x0.12x0.11x0.04x0.02x0.01x0.01x0.01x0.04x-0.02x0.03x0.09x0.00x-
Asset Growth %-49.01%-23.86%14.19%-16.7%-23.28%97.3%-8.44%4.7%97.61%-7.76%-30.94%-13.14%2458.77%-
Total Current Liabilities34.86M38.1M40.28M37.78M22.4M31.38M12.6M12.34M9.33M10.2M7.08M5.49M3.01M3.6M
Accounts Payable0349.99K16.57K1.7M418.36K217.21K270.4K499.51K154.32K655.64K345.96K885K1.25M745K
Days Payables Outstanding59.3449.2-----1.5657.27238.9998.53669--
Short-Term Debt4.5M5.22M4.62M1.78M4.15M7.17M2.93M955.25K02.35M0002.51M
Deferred Revenue (Current)81.28M20.61M22.72M22.72M6.02M5.82M856.49K798.1K623.02K416.68K0144K468K46K
Other Current Liabilities12.72M11.92M12.92M11.58M11.81M18.18M8.54M10.01M8.54M6.77M6.72M4.21M1.39M279K
Current Ratio3.49x3.09x3.95x3.54x7.36x6.94x7.77x10.43x13.28x5.95x9.24x17.82x37.79x1.18x
Quick Ratio3.49x3.09x3.95x3.54x7.36x6.94x7.77x10.43x13.28x5.95x9.24x17.72x37.68x1.18x
Cash Conversion Cycle9.2-----------197.19--
Total Non-Current Liabilities19.19M36.34M41.93M68.81M89.28M78.19M39.01M14.27M10.73M6.35M6.01M4.82M2.83M991K
Long-Term Debt0004.74M4.56M44.71M19.81M14.27M8.04M6.35M4.85M4.82M2.81M943K
Capital Lease Obligations42.12M11.21M11.46M15.28M14.74M16.77M19.2M0000015K48K
Deferred Tax Liabilities00000000000000
Other Non-Current Liabilities000000002.69M01.16M000
Total Liabilities54.05M74.44M82.22M106.59M111.68M109.57M51.61M26.61M20.06M16.54M13.09M10.31M5.84M4.59M
Total Debt13.19M16.43M16.08M21.8M23.45M68.66M41.94M15.22M8.04M8.7M4.85M4.84M2.86M3.54M
Net Debt-103.89M-92.1M-138.63M-109.57M-77.7M-144.6M-50.85M-110.44M-112.65M-49.06M-57.59M-90.03M-109.87M-589K
Debt / Equity0.17x0.28x0.18x0.48x0.33x0.53x0.61x0.14x0.08x0.18x0.09x0.05x0.03x-
Debt / EBITDA-0.33x-------------
Net Debt / EBITDA2.57x-------------
Interest Coverage--45.75x-24.96x-22.12x-11.50x-16.82x-24.90x-159.14x-44.78x-67.95x-69.16x93.17x80.65x-84.61x
Total Equity79.44M57.99M91.7M45.72M71.17M128.76M69.19M105.33M105.95M47.22M56.05M89.8M109.4M-89K
Equity Growth %55.59%-36.77%100.57%-35.75%-44.73%86.11%-34.31%-0.59%124.37%-15.74%-37.59%-17.92%--
Book Value per Share0.720.551.120.560.992.011.382.573.111.862.403.854.94-0.00
Total Shareholders' Equity79.44M57.99M91.7M45.72M71.58M129.45M69.85M105.88M106.22M47.27M56.05M89.8M109.4M-89K
Common Stock5.74M5.06M4.46M3.72M3.6M3.41M2.65M2.42M1.97M1.75M985.14K934K934K59K
Retained Earnings-487.21M-549.06M-442.32M-442.8M-404.6M-361.37M-315.37M-237.68M-177.69M-143.34M-79.88M-36.63M-15.8M-3.67M
Treasury Stock00000000000000
Accumulated OCI29.49M33.7M28.58M28.69M32.3M34.46M29.26M18.75M12.45M10.22M4.58M1K687K41K
Minority Interest0000-409.82K-686.87K-666.83K-556.76K-262.92K-45.63K0000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Shrinking cash reserves versus burn

Balance Sheet Shrinking Since Early 2024

According to the reported balance sheet, PRQR's total assets fell from $173.9M in 2024Q4 to $133.5M in 2026Q2, a contraction of roughly 23 percent that tracks cash depletion rather than asset growth.

The decline in total assets is driven overwhelmingly by the drop in cash from $154.7M to $117.1M over the period, which suggests the balance sheet is being consumed by operating burn instead of being rebuilt through new capital. Equity has recovered from $27.9M in 2024Q3 to $79.4M in 2026Q2, but this improvement appears to reflect financing or revaluation effects rather than earnings, given the accumulated deficit of roughly -$487M. Investors should monitor whether the equity rebound reflects durable capital raising or simply the timing of liability reductions.

Liquidity Strong Yet Finite Runway

Based on reported figures, PRQR held $117.1M in cash against a current ratio of 3.49 in 2026Q2, a buffer that looks comfortable on paper but is being drawn down by sustained cash outflows.

A current ratio above 3 indicates short-term obligations are well covered, and current liabilities of roughly $54M appear manageable against the cash balance. However, with free cash flow negative in every reported quarter and operating cash outflows of roughly $12M in the latest quarter, the implied runway is finite and warrants further investigation as to how long current cash supports operations. The liquidity position is therefore adequate in the near term but is not self-sustaining.

Low Leverage Reflects Limited Borrowing

As reported in financial statements, PRQR's debt of $13.2M against equity of $79.4M produced a debt-to-equity ratio of 0.17 in 2026Q2, down from 0.63 in 2024Q3.

Leverage has moved lower, but the reduction reflects both debt paydown and a larger equity base rather than a deliberate deleveraging strategy visible in the data. Debt of roughly $13M is modest relative to total assets of $133.5M, which suggests financing risk is limited. The more relevant constraint is equity funding dependence, since the company's operating losses, not its debt load, appear to be the binding pressure on the balance sheet.

Asset Base Is Cash Dominated

Based on EDBL's reported figures, PRQR's assets are concentrated in cash, with $117.1M of $133.5M total assets held as cash in 2026Q2, and property and equipment of only $11.9M.

A cash share near 88 percent indicates an asset-light, cash-dependent structure with no goodwill and modest fixed assets, consistent with a clinical-stage biotechnology model. This profile offers flexibility but also means asset value is largely a function of the cash balance, which is declining. PPE has drifted down from $18.1M in 2024Q1 to $11.9M, a pattern that may indicate reduced investment in infrastructure as spending is constrained.

Deferred Revenue Masks Cash Erosion

Deferred revenue of $28.1M in 2026Q2 may appear to cushion the balance sheet, but it is a collaboration liability that is unwound through future revenue recognition rather than representing cash on hand.

Deferred revenue has fallen from $66.8M in 2024Q1 to $28.1M, and its decline may reflect recognition of prior upfront payments rather than new cash inflows. Because this liability is typically settled through performance obligations instead of repayment, it does not represent a cash claim, yet its shrinkage reduces future revenue visibility. Headline liquidity metrics may therefore overstate the company's underlying financial flexibility if the revenue pipeline is not replenished.

PRQR — Frequently Asked Questions

Quick answers to the most common questions about buying PRQR stock.

What are the total assets of ProQR Therapeutics N.V. (PRQR)?

As of 2025, ProQR Therapeutics N.V. (PRQR) had total assets of $132.4M including $117.6M in current assets.

How much debt does ProQR Therapeutics N.V. (PRQR) have?

ProQR Therapeutics N.V. (PRQR) carries total debt of $16.4M, offset by $108.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of ProQR Therapeutics N.V.?

ProQR Therapeutics N.V. (PRQR) has total shareholders' equity (book value) of $58.0M ($0.55 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is ProQR Therapeutics N.V.'s current ratio and liquidity?

ProQR Therapeutics N.V. (PRQR) reported a current ratio of 3.09x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.